ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

1:00PM-3:00PM: Abstract Number: 1384

Echocardiographic Screening in Childhood Onset Systemic Lupus Erythematosus

Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

1:00PM-3:00PM: Abstract Number: 1376

Eculizumab Is Safe as an Adjunctive Therapy in Systemic Lupus Erythematosus with Severe Refractory Nephritis with or Without Thrombotic Microangiopathy in Children

Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

1:00PM-3:00PM: Abstract Number: 1307

Effect of Romosozumab in Postmenopausal Women with Knee Osteoarthritis: Results from the FRAME Clinical Trial

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1553

Effectiveness and Safety of Adalimumab versus Leflunomide in Patients with Takayasu Arteritis – a Retrospective Cohort Study

Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

1:00PM-3:00PM: Abstract Number: 1435

Effectiveness of Combination Therapy with Tocilizumab and Low-Dose Prednisolone as an Induction Therapy in Biologics-Naïve Patients with Rheumatoid Arthritis: A Prospective, Randomized, Controlled, Open-Label, Multicenter Study

RA – Treatment Poster III

1:00PM-3:00PM: Abstract Number: 1547

Effectiveness of Interleukin-6 Receptor Inhibitors for Polymyalgia Rheumatica

Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

1:00PM-3:00PM: Abstract Number: 1504

Efficacy of Risankizumab in the Treatment of PsA Patients with Limited and Extensive Joint Involvement

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III

1:00PM-3:00PM: Abstract Number: 1508

Enthesitis a Dominant Pathology in Psoriatic Arthritis: Identification and Quantification of Enthesitis Burden by 18F-FDG Total-Body PET/CT Imaging

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III

1:00PM-3:00PM: Abstract Number: 1475

Epidemiology of Acute Ischemic Stroke in Patients with Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

1:00PM-3:00PM: Abstract Number: 1175

Epigenetic Regulation of MicroRNA-126 in Scleroderma Is Associated with Upregulation of DNA Methyltransferase-1, Repression of Endothelial Nitric Oxide Synthase Expression, and Enhanced Platelet Adhesion to Endothelial Cells

Systemic Sclerosis and Related Disorders – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 1143

Epigenome-wide Analysis of Osteoarthritis in the Multicenter Osteoarthritis Study

Genetics, Genomics and Proteomics Poster

1:00PM-3:00PM: Abstract Number: 1155

Epigenome-Wide Integrative Association Study on Spondyloarthritis and Psoriatic Arthritis

Spondyloarthritis Including PsA – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 1229

Erosion Score and Erosive Joint Number Using Radiography: Clinical Implications in Patients with ACPA+ Early RA Treated with Abatacept

Imaging of Rheumatic Diseases Poster

1:00PM-3:00PM: Abstract Number: 1483

Etiology of Elevated Serum Creatinine in Patients with Systemic Lupus Erythematosus at Presentation and Association of Crescents in Renal Biopsy with Rapidly Progressive Renal Failure in a Lupus Cohort

SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

1:00PM-3:00PM: Abstract Number: 1268

Evaluating Numeric Rating Scale Versions of the 3 and 4 Visual Analog Scale (3/4-VAS) Composite Measures in Patients with Active Psoriatic Arthritis from the SELECT-PsA Program

Measures and Measurement of Healthcare Quality Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].